|Chief Executive Officer|
Tapas K. De, PhD
|Extensive industrial experience with both proteins/enzymes and small molecules in formulation and process development, including scale-up/technology transfer. Scientific specializations in parenteral and ocular drug delivery and release kinetics, nanoparticle (ceramic, polymeric, bioadhesive, hydrogel) formulation development, reverse micellar enzymology, enzyme kinetics and reaction mechanism. Expert on nab formulation development and characterization. Developed Abraxane nanoparticle formulation at Abraxis Bioscience, as well as nab-17-AAG, nab-docetaxael, nab-rapamycin, nab-ABI011 etc. Lead formulation scientist for the nab business venture with National and international pharmaceuticals companies.|
|Chief Operating Officer|
Vuong Trieu, PhD
|Founder of IgDraSol and Biomiga Diagnostics. Led the development of Abraxane, nab-docetaxel, nab-rapamycin, nab- 17—AAG, nab-IDN5404. Repositioned Genexol-PM from Korea into a viable product for US market as Abraxane equivalent and as drug-device combination. Conducted a successful EOP2 meeting within 7 months of acquiring the asset.
Abraxis Biosciences,(ABI), Celgene, AME (Eli Lilly), Genetic Therapy Inc. (Novartis), IgDraSol, Sorrento Therapeutics
|Chief Business Officer|
Pyng Soon ESQ., CPA
|Counsel to Murchison & Cumming, LLP previously, in the areas of international law, business litigation and business transactions. Mr. Soon has played an integral part in many business and civil litigation cases . He also has experience with SEC matters including APO/PIPE. A licensed CPA, Mr. Soon previously served as a senior tax consultant at one of the world's "Big 4" accounting companies and corporate controller for a $700 million sales corporation.|
|VP of CMC|
Zachary Yim, PhD
|Highly creative, versatile and productive professional in formulation/drug delivery and product development of biologicals, such as recombinant proteins, monoclonal antibodies, vaccines and small molecules, encompassing all traditional oral and injectable dosages forms as well as novel delivery systems, such as sustained release depots, liposomes, nanoparticles, polymeric micelles and vaccines and drug-device combinations.
Abraxis Biosciences (ABI), Medarex, Curagen, Entremed, Repligen, Centocor, Cytogen, Schering-Plough, Roche
|Director of R&D - Electrochemistry|
Steven T. Miller
|Mr. Miller brings more than 25 years in pharmaceutical drug discovery research experience. He was an integral part of the discovery of the ocular anti-allergy utility of olopatadine (Patanol) and potential backups with related patents and publications. Currently, Mr. Miller is the Director of R&D – Electrochemistry working in the formulation lab in Fort Worth, Texas.
UT Southwestern, Alcon, Alcon/Novartis(NIBR)